ONCOLOGY

More than a million people are diagnosed with cancer each year, and will undergo some type intravenous (IV) therapy during their treatment. Peripheral IVs (PIVs) are the most common invasive medical procedure, and more than 300 million IV catheters are sold in the U.S. every year.*

But according to current medical reports, more than 20% of IVs fail because of infiltration.*

Given the types of drugs needed for cancer treatment, both adult and pediatric oncology patients are particularly at risk when infiltrations and extravasations occur. Every one of these PIV complications is a medication dosing and delivery error that can cause additional patient harm, prolong hospital stays, or increase health care expenses. Any one of these may result in significant legal risk and reputation damage for healthcare providers.

A continuous monitoring device for peripheral IVs is the new and next step for minimizing this potential for patient harm. Immediate warning of infiltrations reduces the risk of injury to every patient with a peripheral IV.

Because this kind of device is always watching the IV site, it gives clinicians a reasonable and less intrusive alternative a central line, and significantly improves the security of a standard unmonitored PIV.

*Helm, R. E., Klausner, J.D., Klemperer, J.D., Flint, L.M., and Huang, E. (2015). “Accepted but Unacceptable: Peripheral IV Catheter Failure.” Journal of Infusion Nursing, 38(3), 189-203.

†Yucha, C. B., M. Hastings-Tolsma, and N.M. Szeverenyi, “Differences Among Intravenous Extravasations Using Four Common Solutions,” J. Intravenous Nurs., 16, 277-281, 1993.